Traders sold shares of Johnson & Johnson (NYSE:JNJ) on strength during trading on Thursday. $99.25 million flowed into the stock on the tick-up and $264.36 million flowed out of the stock on the tick-down, for a money net flow of $165.11 million out of the stock. Of all companies tracked, Johnson & Johnson had the 4th highest net out-flow for the day. Johnson & Johnson traded up $0.81 for the day and closed at $138.10

JNJ has been the subject of several research reports. Zacks Investment Research lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Tuesday, November 27th. ValuEngine upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Thursday, December 13th. Morgan Stanley set a $140.00 target price on Johnson & Johnson and gave the stock a “hold” rating in a research report on Thursday, December 20th. Finally, Citigroup decreased their target price on Johnson & Johnson from $148.00 to $139.00 and set a “neutral” rating for the company in a research report on Wednesday, January 2nd. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have assigned a buy rating to the company. Johnson & Johnson has an average rating of “Hold” and an average target price of $142.81.

The stock has a market cap of $371.42 billion, a PE ratio of 16.88, a P/E/G ratio of 2.12 and a beta of 0.68. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.47 and a quick ratio of 1.20.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, January 22nd. The company reported $1.97 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.95 by $0.02. Johnson & Johnson had a return on equity of 35.63% and a net margin of 18.75%. The business had revenue of $20.39 billion during the quarter, compared to analyst estimates of $20.27 billion. During the same quarter in the previous year, the firm posted $1.74 EPS. The business’s revenue for the quarter was up 1.0% compared to the same quarter last year. Research analysts forecast that Johnson & Johnson will post 8.57 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 12th. Investors of record on Tuesday, February 26th were given a dividend of $0.90 per share. The ex-dividend date was Monday, February 25th. This represents a $3.60 dividend on an annualized basis and a yield of 2.61%. Johnson & Johnson’s dividend payout ratio is currently 44.01%.

Johnson & Johnson declared that its board has initiated a share buyback plan on Monday, December 17th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the company to reacquire up to 1.5% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s board of directors believes its stock is undervalued.

A number of large investors have recently added to or reduced their stakes in the stock. Evolution Wealth Advisors LLC bought a new stake in shares of Johnson & Johnson in the 4th quarter worth $40,000. Crewe Advisors LLC raised its stake in shares of Johnson & Johnson by 75.0% in the 4th quarter. Crewe Advisors LLC now owns 350 shares of the company’s stock worth $45,000 after buying an additional 150 shares in the last quarter. Horan Securities Inc. raised its stake in shares of Johnson & Johnson by 122.3% in the 4th quarter. Horan Securities Inc. now owns 438 shares of the company’s stock worth $56,000 after buying an additional 241 shares in the last quarter. Stuart Chaussee & Associates Inc. raised its stake in shares of Johnson & Johnson by 20.7% in the 4th quarter. Stuart Chaussee & Associates Inc. now owns 466 shares of the company’s stock worth $60,000 after buying an additional 80 shares in the last quarter. Finally, Ruggie Capital Group raised its stake in shares of Johnson & Johnson by 342.5% in the 4th quarter. Ruggie Capital Group now owns 469 shares of the company’s stock worth $60,000 after buying an additional 363 shares in the last quarter. Institutional investors and hedge funds own 66.43% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Traders Sell Shares of Johnson & Johnson (JNJ) on Strength (JNJ)” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.thecerbatgem.com/2019/03/21/traders-sell-shares-of-johnson-johnson-jnj-on-strength-jnj.html.

About Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: Earnings Per Share (EPS)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.